Saturday 17 October 2026 Export INFU’s income statement to Excel — free account

InfuSystems Holdings, Inc.

InfuSystems Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $143.4 million, up 6.36% from fiscal 2024. In the quarter to June 2026, revenue grew 2.59%, EPS grew 33.3%, free cash flow fell 66.5% and total debt fell 22.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

13.33 0.59 −4.24%

Follow INFU

Alert me

Market cap: $277.2M
P/E: 31.7×
Fwd P/E: 21.7×
Dividend yield: —
F-score: 8/9
Altman Z: 3.74
Beneish M: −3.30
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.15

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	3	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 6.33%

Capital & Financial Ratios $m

Market Cap 277.24

Revenue 143.34

Net Income 8.54

Free Cash Flow 15.14

Net Debt 19.46

Current Ratio 2.50

Debt/Equity 0.35

P/E ratio 31.74

Fwd P/E 21.70

P/S ratio 1.87

P/B ratio 4.52

Past 5Y EPS Growth (17.27%)

This Y EPS Growth 48.39%

Next Y EPS Growth 23.19%

Next Y revenue growth 1.23%

Next 5Y EPS Growth 25.31%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 36.76%

10-year low 10-year high

P/S against its own 10 years 75.75%

10-year low 10-year high

P/B against its own 10 years 73.39%

10-year low 10-year high

EV/Sales against its own 10 years 68.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	0	1	3	1
Receivables	20	21	23	27
Inventory	6	7	5	6
Other	4	4	5	5
	31	32	36	38

	2023	2024	2025	Q'26
Payables	8	10	11	9
ST’ Debt	—	—	—	—
Other	8	8	9	6
	16	18	20	15

Compound Annual Growth %

	10y	5y	3y
Sales	7.35%	8.05%	9.28%
Cash Flow	13.22%	3.78%	11.69%
Earnings	9.06%	(17.49%)	616.72%
Book Value	1.31%	7.06%	6.09%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	34	37	—	—	—
’25	35	36	36	36	143
’24	32	34	35	34	135
’23	30	32	32	32	126
’22	27	27	27	29	110
’21	24	25	27	27	102
’20	22	26	25	25	97

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	7	—	—	—
’25	2	7	8	7	24
’24	0	2	10	8	20
’23	0	2	4	5	11
’22	4	5	3	5	18
’21	3	6	6	4	18
’20	1	4	8	8	20

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	2	—	—	—
’25	(1)	7	8	5	19
’24	0	(4)	7	5	7
’23	(3)	0	4	4	4
’22	2	3	0	2	6
’21	1	4	2	(2)	5
’20	(3)	(1)	8	4	8

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.05	0.15	—	—	—
’25	(0.01)	0.12	0.11	0.10	0.31
’24	(0.05)	0.03	0.08	0.04	0.11
’23	(0.02)	0.02	0.03	0.00	0.04
’22	(0.02)	(0.01)	0.02	0.01	0.00
’21	0.03	0.04	(0.02)	0.02	0.06
’20	(0.02)	0.19	0.14	0.49	0.80

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1.55	1.20	2.20	3.33	5.26	12.51	6.10	6.68	5.74	4.61	Analyst estimates 2026–2028 Powerpack
	High	3.75	2.60	3.65	8.78	19.68	23.26	17.54	11.44	10.58	11.04
People
People	Employees	250	245	251	269	292	407	438	516	514	473
	Revenue/emp, $m	0.28	0.29	0.27	0.30	0.33	0.25	0.25	0.24	0.26	0.30
Income, $m
Income, $m	Revenue	70	71	67	81	97	102	110	126	135	143
	Gross margin, %	63.46	61.01	58.94	57.80	60.33	57.17	55.10	50.17	52.20	55.98
	EBT	0	(5)	(1)	2	8	1	0	2	5	11
	EBT margin, %	(0.52)	(7.40)	(1.55)	1.88	7.75	1.23	0.12	1.47	3.75	7.41
	Net income	0	(21)	(1)	1	17	1	0	1	2	7
	Depreciation	11	13	11	12	14	15	13	13	13	13
Per share, $
Per share, $	Revenue	3.12	3.13	3.13	4.11	4.84	4.99	5.32	5.98	6.34	6.94
	Earnings	(0.01)	(0.91)	(0.05)	0.07	0.86	0.07	0.00	0.04	0.11	0.32
	Cash flow	0.35	0.34	0.53	0.70	1.01	0.89	0.85	0.53	0.96	1.18
	Capex	(0.22)	0.04	(0.23)	(1.00)	(0.60)	(0.65)	(0.56)	(0.32)	(0.62)	(0.26)
	Free cash flow	0.13	0.38	0.30	(0.29)	0.40	0.24	0.29	0.21	0.34	0.92
	Book value	2.24	1.36	0.95	1.13	2.03	2.35	2.32	2.49	2.70	2.78
	Shares, m	23	23	21	20	20	21	21	21	21	21
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	121.86	21.59	243.29	0.00	267.45	84.50	28.03
	P/S	0.79	0.75	1.10	2.07	3.88	3.41	1.63	1.70	1.33	1.29
	P/B	1.09	1.73	3.60	7.54	9.27	7.24	3.74	4.10	3.12	3.23
	EV/Sales	1.23	1.10	1.54	2.52	4.18	3.73	1.94	1.93	1.51	1.41
	EV/FCF	(11.41)	(18.82)	(15.65)	(10.87)	(83.42)	(47.69)	(30.60)	(28.60)	(35.20)	33.45
Cash, $m
Cash, $m	Operating cash flow	8	8	11	14	20	18	18	11	20	24
	Capex	(5)	1	(5)	(20)	(12)	(13)	(11)	(7)	(13)	(5)
	Free cash flow	3	9	6	(6)	8	5	6	4	7	19
Balance, $m
Balance, $m	Working capital	4	5	3	(3)	7	9	10	15	15	16
	Total debt	34	28	34	38	39	33	33	29	24	20
	Net debt	31	25	29	36	29	33	33	29	23	16
	Shareholders’ equity	51	31	20	22	41	48	48	52	58	57
Returns, %
Returns, %	ROA	(0.23)	(25.07)	(1.65)	1.90	19.67	1.46	0.02	0.86	2.27	6.49
	ROIC	0.74	(4.26)	0.52	3.79	7.89	2.17	1.28	3.15	5.33	10.10
	ROE	(0.44)	(50.73)	(4.26)	6.36	54.95	3.19	0.04	1.74	4.27	11.54

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RCEL Avita Medical Inc.	$333.1M	— (loss-making)	— (loss-making)	+17.83% (above 0%: growing)	n/m	+66.52% (above 0%: growing)	81.87%	(28.42%)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
Median of peers	$267.5M	—	—	−1.25%	—	−7.70%	78.59%	(90.09%)

All 149 Medical Devices stocks →

InfuSystems Holdings, Inc. (INFU) key facts

Strength: InfuSystems Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $143.4 million, up 6.36% from fiscal 2024.
InfuSystems Holdings, Inc. (INFU) is a Medical Devices company in the Healthcare sector, listed on NYSE American.
As of October 16, 2026, INFU traded at $13.33, a market capitalization of $277.2 million.
Return on equity was 11.5% and debt-to-equity 0.35.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 3.74 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.